Sleep Apnea Raises Gout Risk

Save

Patients with obstructive sleep apnea were at increased risk for incident gout, particularly in the first years after the sleep apnea diagnosis, U.K. researchers reported.

Adherence to Gout Therapies Painfully Low

Save

A retrospective study of the large UK Clinical Practice Research Datalink assessed patient compliance in gout and found that adherence to allopurinol is poor, especially among females and younger patients and those with fewer comorbidities.

Not All Hyperuricemia Leads to Gout

Save

Dalbeth and colleagues studied 4 large prospective cohorts and found that rising levels of serum uric acid (SUA) leads to a non-linear increased risk of incident gout, but only half of those with SUA ≥10mg/dL developed clinically evident gout. 

The RheumNow Week in Review – No Good Gout (8.10.18)

Save

Dr. Jack Cush reviews the news and latest journal articles from the past week on RheumNow.com. Info on Surgery and Hip Fractures, Gout drugs abandoned, Allopurinol escalation, hydroxychloroquine drug levels, how to treat scleroderma in India and exactly who gets back pain.

Selective Use of HLA-B*5801 Testing in Gout

Save

The current edition of JAMA Internal Medicine describes an Asian gout patient who presents with an allopurinol hypersensitivity reaction that could have been diagnosed by testing for HLA-B*5801.

Febuxostat (IR or XR) Effective in Gout with Renal Impairment

Save

Saag and colleagues report the results of a 3 month phase III trial demonstrating equal efficacy between febuxostat extended release (XR) and immediate release (IR) formulations in patients with gout.  and normal or impaired renal function.

The Fate of Palindromic Rheumatism

Save

Palindromic rheumatism (PR) is an intermittent inflammatory arthropathy with episodes of arthritis and/or periarticular inflammation that wax and wane over time. It is thought that up to one-third of such patients may go on to develop rheumatoid arthritis (RA).

The RheumNow Week in Review – Lupus in the News (7.27.18)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Steroids vs. NSAIDs in Treating Acute Gout

Save

Gout, the ancient disease of kings is usually treated with the ancient (and costly) drug colchicine, often without consideration of nonsteroidal antiinflammatory drugs (NSAID) or corticosteroids.

Erectile Dysfunction in Gout

Save

The Journal of Rheumatology reports a population-based study demonstrating that gout is associated with an increased risk of developing erectile dysfunction (ED) suggesting that hyperuricemia and inflammation may be independent risk factors for ED.

Immunophysiology of the Gout Attack

Save

Gout may be an ancient disease, with arthritis of the big toe having been described in Egypt in 2,600 BC, but only now are the underlying pathophysiologic events being elucidated and understood.

Obesity, Hypertension and Diuretics Drive Gout Risk

Save

A recent metanalysis suggests that obesity, hypertension and diuretic use are associated with a two-fold increased risk of incident gout.

From a potential of 9923 articles, researchers analyzed 11 studies with data suitable for the meta-analysis.

The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)

Save

Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.

Public Citizen Pressures FDA to Pull Febuxostat

Save

Public Citizen has petitioned the U.S. Food and Drug Administration (FDA) to remove Takeda's drug febuxostat (Uloric) from the market, citing the FDA's own warnings and evidence of serious cardiovascular harms. This follows on a recent FDA safety warning and NEJM paper citing cardiovascular concerns over febuxostat.

The RheumNow Week in Review – EULAR18 Epilogue (6.22.18)

Save

Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from RheumNow.com, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.

Gout Takeaways

Save

The annual EULAR meeting just came to an end today. Rooms are gradually emptying out. People look both content to have updated their knowledge and relieved that four very busy days have concluded. Time to summarize.

EULAR 2018 - Day 1 Report

Save

Highlights from the first day at EULAR include: canakinumab prevents acute gout; AS uveitis benefits from most TNFi; MRI does not improve T2Tor X-ray outcomes; baracitinib wins in SLE - maybe?; new lupus criteria; and lost survival in RA. Here's the RheumNow recap. 

The RheumNow Week in Review – Baricitinib Splash (6.7.18)

Save

Dr. Jack Cush discusses the past week's news and journal articles featured on RheumNow.com - including reports on advance practice clinicians, baricitinib, gout, disease activity, hypomagnesemia and upadacitinib.

Sons of Gout Study

Save

The genetics and heritability of gout has suggested a higher risk in certain families.  A UK cohort study examined the prevalence of gout and monosodium urate (MSU) crystal deposition among those at risk (sons of gout patients) for gout and found a high incidence of hyperuricemia and MSU crystal deposition.

The RheumNow Week in Review – Modifiable Behavior (5.18.18)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis, and modifiable behaviors that influence outcomes.